ESTRO 2025 - Abstract Book

S4213

RTT - Patient experience and quality of life

ESTRO 2025

Results: 83 patients were included, 48 were men and 35 women. Patients were between 42 and 96 years old. 54 patients had WHO 1-2 and 17 patients had WHO 3 when treatment started. 10 patients had 2 targets and about 84% of the targets were vertebrae. 58 targets were treated with 8 Gy/1 fraction and 27 were treated with 16 Gy/2 fractions. 8 targets were treated with five fractions during the quality assurance period. Of the 58 targets treated with 8 Gy/1 fraction, 30 targets (approx. 51%) had moderate to good treatment effect. Of the 27 targets treated with 16Gy/2 fractions, 20 targets (approx. 74 %) had moderate to good treatment effect. Of the 8 targets treated with 20 Gy/5 fractions, 50 % (4 targets) had moderate to good effect. 20 % of the targets had no pain-relieving effect and 20 targets had unclear effect due to no pain before treatment, or the patient was deceased or seriously ill at the time of the follow-up. 10 patients were deceased after 6 weeks, although two of the patients did have an effect of the treatment prior to death according to medical records. Some patients experienced better mobility but the same pain level. Side effects such as crooked tongue during a transient period and inability to open the mouth were unexpected findings, as well as a skin reaction 4 weeks after treatment. During follow-up, supported conversations were conducted and seven patients were referred to health services for medical support. Conclusion: About 64 % of the total had good or moderate effect of the treatment. A study was started in the spring of 2024 to further evaluate. This study aims to ensure treatment effect, evaluate quality of life at the start and six weeks after the treatment, and gain an insight into how patients experience the treatment process. The plan is to include 200 250 patients. Digital Poster Perceived spouses supportive and unsupportive behaviors in women with breast cancer during treatment Nadia Bouzid, Imene Meddeb, Rym zanzouri, Bochra Naija, Ons Bettaieb, Amal chamsi, Dalia Yazid, Sabrine Tbessi, Samia Kanoun, Sameh Tebra Radiation oncology, Farhat Hached, sousse, Tunisia Purpose/Objective: Breast cancer diagnosis is a life-changing event, for the patients and their partners, and it can affect profoundly the couple’s life in more ways than one. The support of the spouse is very crucial in the fight against cancer. The aim of this study was to describe perceived partner’s response in women with breast cancer during treatment. Material/Methods: A descriptive cross-sectional study carried out with non-metastatic breast cancer patients, undergoing treatment in the radiation oncology department of Farhat Hached Hosital in Sousse, Tunisia, during a period of two months (september-october 2024). Socioeconomic variables and clinical history were collected. The variable spouses response was measured through the validated Partner Responses to Cancer Inventory (PRCI). Results: A total of 80 patients were included in this study. The average age of our patients was 51.4 [34-72]. 57.14% of patients are from urban areas. The average marriage length is 27 years [7-46]. The average number of children among participants is 2.76, with an overall high marital satisfaction rate of 86%. However, the support provided by spouses during the illness varied greatly between patients. 54% of patients reported no change in spousal support, 33% noted an increase, and 13% experienced a decrease. Among the 88% Keywords: Palliative, Bone metastases, Pain 4501